Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CNTN NASDAQ:ETON NASDAQ:PHAR NASDAQ:PHAT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTNHillstream Biopharma$3.52+5.1%$3.40$1.08▼$9.08$245.71M1.44760,789 shs514,095 shsETONEton Pharmaceuticals$32.70-6.6%$25.52$13.09▼$35.66$895.52M0.82356,481 shs445,297 shsPHARPharming Group$12.67-1.1%$15.63$9.54▼$21.34$894.75M0.0423,084 shs22,359 shsPHATPhathom Pharmaceuticals$11.35-2.0%$11.68$3.92▼$18.31$905.28M0.571.20 million shs533,259 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTNHillstream Biopharma+3.08%-10.67%+0.90%+334,999,900.00%+334,999,900.00%ETONEton Pharmaceuticals+1.60%+16.82%+48.68%+95.20%+72.92%PHARPharming Group-0.47%-1.16%-25.29%-21.70%+22.12%PHATPhathom Pharmaceuticals-2.44%-11.26%-10.09%+1.40%+196.92%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCNTNHillstream Biopharma$3.52+5.1%$3.40$1.08▼$9.08$245.71M1.44760,789 shs514,095 shsETONEton Pharmaceuticals$32.70-6.6%$25.52$13.09▼$35.66$895.52M0.82356,481 shs445,297 shsPHARPharming Group$12.67-1.1%$15.63$9.54▼$21.34$894.75M0.0423,084 shs22,359 shsPHATPhathom Pharmaceuticals$11.35-2.0%$11.68$3.92▼$18.31$905.28M0.571.20 million shs533,259 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCNTNHillstream Biopharma+3.08%-10.67%+0.90%+334,999,900.00%+334,999,900.00%ETONEton Pharmaceuticals+1.60%+16.82%+48.68%+95.20%+72.92%PHARPharming Group-0.47%-1.16%-25.29%-21.70%+22.12%PHATPhathom Pharmaceuticals-2.44%-11.26%-10.09%+1.40%+196.92%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCNTNHillstream Biopharma 1.00SellN/AN/AETONEton Pharmaceuticals 2.40Hold$41.0025.40% UpsidePHARPharming Group 2.40Hold$38.33202.58% UpsidePHATPhathom Pharmaceuticals 2.88Moderate Buy$25.00120.26% UpsideCurrent Analyst Ratings BreakdownLatest CNTN, PHAT, PHAR, and ETON Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026CNTNHillstream Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/15/2026ETONEton Pharmaceuticals HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$52.00 ➝ $57.005/11/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D)4/27/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)4/21/2026ETONEton Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/21/2026PHATPhathom Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/17/2026ETONEton Pharmaceuticals Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold4/13/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold (C-) ➝ Sell (D+)4/10/2026PHARPharming Group Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold4/10/2026PHARPharming Group Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$37.003/30/2026PHARPharming Group Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)(Data available from 5/22/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCNTNHillstream BiopharmaN/AN/AN/AN/A$6.73 per shareN/AETONEton Pharmaceuticals$79.95M11.20$0.00 per share6,646.47$1.12 per share29.19PHARPharming Group$369.49M2.42$0.20 per share64.17$3.81 per share3.33PHATPhathom Pharmaceuticals$175.11M5.17N/AN/A($4.22) per share-2.69Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCNTNHillstream Biopharma-$35.92M-$1.15N/AN/AN/AN/A-31.50%-24.72%N/AETONEton Pharmaceuticals-$4.60M-$0.07N/A17.96N/A-1.70%-5.68%-1.49%8/6/2026 (Estimated)PHARPharming Group$2.85M$0.1679.1919.49N/A3.30%4.64%2.55%7/30/2026 (Estimated)PHATPhathom Pharmaceuticals-$221.25M-$2.12N/A7.28N/A-76.77%N/A-44.29%8/6/2026 (Estimated)Latest CNTN, PHAT, PHAR, and ETON EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026ETONEton Pharmaceuticals$0.10$0.05-$0.05$0.05$22.31 million$24.27 million5/13/2026Q1 2026CNTNHillstream BiopharmaN/A-$0.23N/A-$0.23N/AN/A5/7/2026Q1 2026PHARPharming Group$0.05-$0.07-$0.12-$0.07$92.06 million$72.45 million3/31/2026Q4 2025CNTNHillstream BiopharmaN/A$0.54N/A$0.54N/AN/A3/19/2026Q4 2025ETONEton Pharmaceuticals$0.12$0.05-$0.07$0.05$20.58 million$21.28 million3/12/2026Q4 2025PHARPharming Group$0.15$0.07-$0.08$0.07$111.76 million$106.50 million2/26/2026Q4 2025PHATPhathom Pharmaceuticals-$0.09-$0.08+$0.01-$0.29$57.44 million$57.58 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCNTNHillstream BiopharmaN/AN/AN/AN/AN/AETONEton PharmaceuticalsN/AN/AN/AN/AN/APHARPharming GroupN/AN/AN/AN/AN/APHATPhathom PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCNTNHillstream BiopharmaN/A37.7637.76ETONEton Pharmaceuticals0.621.210.88PHARPharming Group0.352.632.06PHATPhathom PharmaceuticalsN/A2.212.16Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCNTNHillstream Biopharma1.16%ETONEton Pharmaceuticals27.86%PHARPharming Group0.03%PHATPhathom Pharmaceuticals99.01%Insider OwnershipCompanyInsider OwnershipCNTNHillstream Biopharma6.70%ETONEton Pharmaceuticals16.49%PHARPharming Group2.07%PHATPhathom Pharmaceuticals9.33%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCNTNHillstream Biopharma269.81 million65.13 millionN/AETONEton Pharmaceuticals2027.39 million22.88 millionOptionablePHARPharming Group28070.63 million69.16 millionNot OptionablePHATPhathom Pharmaceuticals11079.76 million72.32 millionOptionableCNTN, PHAT, PHAR, and ETON HeadlinesRecent News About These CompaniesPhathom Pharmaceuticals to Participate in Upcoming Investor ConferencesMay 22 at 8:00 AM | globenewswire.comPhathom Pharmaceuticals Inc Ordinary shares PHATMay 21 at 10:40 PM | morningstar.comMPhathom Pharmaceuticals Highlights Breadth of Independent Vonoprazan Research at Digestive Disease Week 2026 Annual MeetingMay 20 at 8:00 AM | globenewswire.comWhy Phathom Pharmaceuticals, Inc.’s (PHAT) Stock Is Down 6.78%May 17, 2026 | aaii.comAPhathom Pharmaceuticals Signals Strong Growth on Earnings CallMay 16, 2026 | theglobeandmail.comPhathom Pharmaceuticals Announces $130 Million Public OfferingMay 12, 2026 | theglobeandmail.comPhathom Pharmaceuticals, Inc. (NASDAQ:PHAT) Given Consensus Recommendation of "Moderate Buy" by BrokeragesMay 9, 2026 | marketbeat.comPhathom Pharmaceuticals (PHAT) Is Up 11.0% After Narrowing Q1 Loss And Reaffirming 2026 Profitability TimelineMay 5, 2026 | finance.yahoo.comHow The Phathom Pharmaceuticals (PHAT) Narrative Is Shifting Around Profitability And Exclusivity RisksMay 5, 2026 | finance.yahoo.com147,000 Shares in Phathom Pharmaceuticals, Inc. $PHAT Purchased by Hussman Strategic Advisors Inc.May 3, 2026 | marketbeat.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Phathom Pharmaceuticals (PHAT), TELA Bio (TELA) and Nanobiotix (NBTX)May 2, 2026 | theglobeandmail.comAnalysts Offer Insights on Healthcare Companies: Amgen (AMGN), Phathom Pharmaceuticals (PHAT) and Zimmer Biomet Holdings (ZBH)May 2, 2026 | theglobeandmail.comPhathom Pharmaceuticals, Inc. Q1 2026 Earnings Call SummaryMay 2, 2026 | finance.yahoo.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Up 7.5% - Should You Buy?May 1, 2026 | marketbeat.comPhathom Pharmaceuticals to Highlight VOQUEZNA® (vonoprazan) at DDW 2026 Annual MeetingMay 1, 2026 | globenewswire.comPhathom Pharmaceuticals (NASDAQ:PHAT) Releases Earnings Results, Misses Estimates By $0.01 EPSApril 30, 2026 | marketbeat.comPhathom Pharmaceuticals, Inc. 2026 Q1 - Results - Earnings Call PresentationApril 30, 2026 | seekingalpha.comPhathom Pharmaceuticals Q1 Earnings Call HighlightsApril 30, 2026 | marketbeat.comPhathom Pharmaceuticals, Inc. (PHAT) Q1 2026 Earnings Call TranscriptApril 30, 2026 | seekingalpha.comPhathom Pharmaceuticals (NASDAQ:PHAT) Stock Price Down 16.2% After Earnings MissApril 30, 2026 | marketbeat.comPhathom Pharmaceuticals, Inc. (PHAT) Reports Q1 Loss, Tops Revenue EstimatesApril 30, 2026 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All Headlines3 Healthcare Stocks Set to Benefit From the One Big Beautiful BillBy Chris Markoch | May 10, 2026The Most Important Part of These 3 Big Pharma Earnings Reports Wasn’t the BeatBy Jessica Mitacek | May 2, 2026Hims & Hers Stock Plunges After Q1 Miss: Is the GLP-1 Pivot Enough to Fuel a Recovery?By Jessica Mitacek | May 12, 20262 Ways to Play the Big Pharma Patent CliffBy Nathan Reiff | May 15, 2026Mirum Pharma: A Rare Disease Growth Story to WatchBy Chris Markoch | May 20, 2026CNTN, PHAT, PHAR, and ETON Company DescriptionsHillstream Biopharma NASDAQ:CNTN$3.52 +0.17 (+5.07%) Closing price 03:59 PM EasternExtended Trading$3.52 0.00 (0.00%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Hillstream BioPharma, Inc., a pre-clinical biotechnology company, develops novel therapeutic candidates targeting ferroptosis, an anti-cancer mechanism resulting in iron mediated cell death (IMCD) for the treatment resistant cancers. The company's product candidate is HSB-1216, an IMCD inducer targeting solid tumors. It also develops HSB-888, a dual Quatramer loaded IMCD inducer coupled with its anthracycline analogue for solid tumors; HSB-510, a targeted bifunctional inhibitory compound in Quatramer with single digit nanomolar; IC50 against PI3K-delta and HDAC6, which is also known to downregulate; c-myc, a cancer drug target; and HSB-114, an immunotherapeutic agent, which uses its Quatramer technology to deliver tumor necrosis factor-alpha gene into cancer cells. The company was incorporated in 2019 and is based in Bridgewater, New Jersey.Eton Pharmaceuticals NASDAQ:ETON$32.70 -2.31 (-6.59%) Closing price 03:59 PM EasternExtended Trading$32.55 -0.15 (-0.44%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.Pharming Group NASDAQ:PHAR$12.67 -0.14 (-1.10%) Closing price 03:59 PM EasternExtended Trading$12.70 +0.03 (+0.21%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also develops OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of HAE. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105. Pharming Group N.V. was incorporated in 1988 and is headquartered in Leiden, the Netherlands.Phathom Pharmaceuticals NASDAQ:PHAT$11.35 -0.23 (-1.99%) Closing price 03:59 PM EasternExtended Trading$11.34 -0.01 (-0.13%) As of 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Deere Beats Q2 Estimates, But Ag Weakness Weighs on Outlook NVIDIA Price Pullback? Don’t Count on It, Business Is Accelerating Meta Platforms 10% Layoff Raises a Bigger Question About AI Spending Intuit's Great SaaS Reset: Fired By AI Biogen Stock Slides After Trial Miss, But Analysts Stay Bullish Target Shows Strengths, But Analysts Want to See More Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
